Laurus Labs share price
You have to be logged in to add this to Watchlist.- ₹827.15(0.68%)July 18, 2025 15:29:56 PM IST
- NSE
- BSE
- Vol : 1.05M (NSE + BSE)Last 20 day avg : 2.59 M
Laurus Labs is trading 0.68% upper at Rs 827.15 as compared to its last closing price. Laurus Labs has been trading in the price range of 829.95 & 814.80. Laurus Labs has given 36.30% in this year & 3.53% in the last 5 days. Laurus Labs has TTM P/E ratio 92.17 as compared to the sector P/E of 25.87.There are 11 analysts who have initiated coverage on Laurus Labs. There are - analysts who have given it a strong buy rating & - analysts have given it a buy rating. - analysts have given the stock a sell rating.The company posted a net profit of 233.67 Crores in its last quarter.Listed peers of Laurus Labs include Glenmark Pharmaceuticals (-0.16%), Biocon (0.52%), Laurus Labs (0.68%).The Mutual Fund holding in Laurus Labs was at 6.88% in 31 Mar 2025. The MF holding has decreased from the last quarter. The FII holding in Laurus Labs was at 25.51% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Jul 19, 2025, 12:09 AM UTC
- Dividend YieldLower than industry0.15Annual dividends as a percentage of the stock price.
- P/BHigher than historical values9.36The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values116.85Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.81Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.62The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 19.49% from Rs 1720.30 crore to Rs 1439.67 crore, year-on-year
- The company has grown its March quarter profit by 209.05% from Rs 75.61 crore to Rs 233.67 crore, year-on-year
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 804.80
- R2
- 884.70
- R3
- 934.95
- S1
- 674.65
- S2
- 624.40
- S3
- 544.50
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | Bullish | 2,223.05 | -0.16 | 62,734.65 | 37.95 | 5.69 | 0.14 | 7.90 |
| Biocon | Bullish | 398.90 | 0.52 | 53,365.10 | 47.70 | 2.08 | 0.13 | 59.81 |
| Laurus Labs | Bullish | 827.15 | 0.68 | 44,630.49 | 129.29 | 9.15 | 0.16 | 15.82 |
| Suven Pharmaceuticals | Neutral | 1,071.50 | -1.97 | 40,005.70 | 96.40 | 15.12 | - | 10.36 |
| Ipca Laboratories | Moderately Bullish | 1,472.00 | -0.15 | 37,297.86 | 40.79 | 5.17 | 0.28 | 8.55 |
- Pledged found - Promoter(s) have pledged 2.69% of shares.
- Pledging Flat - Promoter(s) pledging has not increased in last quarter.
- Promoter(s) does not have a high stake in the company
- Promoter(s) have increased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has decreased by 0.05 percentage points from previous quarter
- Mutual Funds holding has decreased by 0.74 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-07-25 | Quarterly Results |
| 2025-04-24 | Audited Results & Interim Dividend |
| 2025-01-24 | Quarterly Results |
| 2024-10-24 | Quarterly Results & Interim Dividend |
| 2024-07-25 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE947Q01028
- BSE Code540222
- NSE CodeLAURUSLABS
Laurus Labs is trading at 827.15 as on Fri Jul 18 2025 09:59:56. This is 0.68% upper as compared to its previous closing price of 821.55.
The market capitalization of Laurus Labs is 44630.49 Cr as on Fri Jul 18 2025 09:59:56.
The 52 wk high for Laurus Labs is 834.45 whereas the 52 wk low is 390.30
Laurus Labs can be analyzed on the following key metrics -
- TTM P/E: 92.17
- Sector P/E: 25.87
- Dividend Yield: 0.15%
- D/E ratio: 0.62
Laurus Labs reported a net profit of 358.32 Cr in 2025.
The Mutual Fund Shareholding was 6.88% at the end of 31 Mar 2025.